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Abstract
Introduction Laboratory and epidemiologic studies have
suggested a modifying effect of cardiac glycosides (for example,
digoxin and digitoxin) on cancer risk. We explored the
association between digoxin treatment and invasive breast
cancer incidence among postmenopausal Danish women.
Methods We used Danish registries to identify 5,565
postmenopausal women diagnosed with incident invasive
breast carcinoma between 1 January 1991 and 31 December
2007, and 55,650 matched population controls. Cardiac
glycoside prescriptions were ascertained from county
prescription registries. All subjects had at least 2 years of
recorded prescription drug and medical history data. We
estimated the odds ratio associating digoxin use with breast
cancer in conditional logistic regression models adjusted for
age, county of residence, and use of anticoagulants, non-
steroidal anti-inflammatory drugs (NSAIDs), aspirin, and
hormone replacement therapy. We also explored the impact of
confounding by indication and detection bias.
Results Digoxin was the sole cardiac glycoside prescribed to
subjects during the study period. There were 324 breast cancer
cases (5.8%) and 2,546 controls (4.6%) with a history of
digoxin use at least 1 year before their index date (adjusted odds
ratio (OR): 1.30; 95% confidence interval: 1.14 to 1.48). The
breast cancer OR increased modestly with increasing duration
of digoxin exposure (adjusted OR for 7 to 18 years of digoxin
use: 1.39; 95% confidence interval: 1.10 to 1.74). The
association was robust to adjustment for age, receipt of
hormone replacement therapy, coprescribed drugs, and
confounding by indication. A comparison of screening
mammography rates between cases and controls showed no
evidence of detection bias.
Conclusions Our results suggest that digoxin treatment
increases the risk of invasive breast cancer among
postmenopausal women.
Introduction
Cardiac glycosides (CGs) are natural steroid toxins that have
been used since the 18th century to treat congestive heart fail-
ure (CHF) and atrial fibrillation (AF) [1]. The clinically most
prevalent CGs are the Digitalis-derived cardenolides digitoxin
and digoxin. These compounds exert their pharmacologic
effect via inhibition of the Na+/K+ ATPase, which indirectly
raises intracellular Ca2+ concentration, thus increasing the
force of contractility in cardiac myocytes.
In 1979, Stenkvist et al. reported an unusual finding in a small
cohort of breast cancer patients (n = 142) [2]. Women in the
cohort who were taking CGs (mostly digoxin) at the time of
their breast cancer diagnosis had tumors with less aggressive
phenotypes than breast tumors of women not taking CGs [2].
They later reported a higher recurrence rate among the women
not taking CGs after 5 [3] and approximately 22 [4] years of
follow-up. These observations suggested a beneficial effect of
cardiac glycosides for women with breast tumors. An early
mechanistic hypothesis centered on CG interference with
estrogen receptor (ER) signaling in tumor cells [2], while cur-
rent laboratory studies implicate novel signaling pathways
mediated by the Na+/K+ ATPase [5,6].
AF: atrial fibrillation; BMI: body mass index; CG: cardiac glycoside; CHF: congestive heart failure; CI: confidence interval; CVD: cardiovascular dis-
ease; ER: estrogen receptor; HRT: hormone replacement therapy; ICD: International Classification of Diseases; OR: odds ratio; SIR: standardized 
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Subsequent studies of the association between CG use and
breast cancer incidence gave conflicting results. Haux et al.
compared site-specific cancer incidence rates among digi-
talis-treated Norwegians patients with expected rates in the
general population [7]. Several cancers, including female
breast cancer, occurred at higher rates among those treated
with digitalis compared with the general population [7]. Also,
Friedman reported no association between CG prescription
history and breast cancer in a Kaiser-Permanente registry
study [8].
Given the continued importance of CG medicines to treat
heart disease and the inconsistent results from earlier studies
of the association between this therapy and breast cancer
occurrence, we examined the association between digoxin
treatment and breast tumor incidence rate in a population-
based prospective case-control study of postmenopausal
Danish women.
Materials and methods
This study was approved by the Boston University Medical
Campus Institutional Review Board and the Danish Registry
Board.
Study population
This study was conducted within the female population of
North Jutland and Aarhus Counties, Denmark [9]. We used
county hospital registries to ascertain all cases of incident
invasive breast cancer diagnosed in women age 55 or older.
Ascertainment began on 1 January 1991 in North Jutland
County and 1 January 1998 in Aarhus County, and continued
until 31 December 2007 [10]. The hospital registries contain
data on patients' civil personal registry (CPR) number, date(s)
of admission, date(s) of discharge, and up to 20 discharge
diagnoses and medical procedures per discharge or outpa-
tient visit. Diagnoses are assigned by the attending physician,
and are coded according to the International Classification of
Diseases, 8th revision (ICD-8, until 1995) and 10th revision
(ICD-10, 1995 onwards).
Controls were identified in the Danish Civil Registration Sys-
tem, which has tracked residential address, vital status, and
date of emigration for the entire Danish population since 1968
[11]. Controls were selected for each case by risk-set sam-
pling, matching controls to cases on year of birth and county
of residence. Within strata of the matching factors, we
selected 10 controls at random among those who were alive
and without a history of breast cancer on the date of the
matched case's diagnosis. This date was the index date for the
cases and matched controls.
Data collection
We used each subject's unique CPR number to link the case-
control roster to county prescription databases [12,13], which
automatically record all prescriptions filled since 1989 in North
Jutland County and 1996 in Aarhus County. The databases
encode drugs by the Anatomical Therapeutic Chemical (ATC)
classification system [14] and record dates of all prescription
fills along with the patient's CPR number. These systems
report prescription data to the county databases, as well as to
the Danish National Health Service, which refunds a portion of
medication costs. Prescriptions are logged in the registries
after patients present to a pharmacy and pay their share of the
prescription cost. To ensure adequate prescription data his-
tory, we excluded cases and controls who had lived in the
study counties for less than 2 years after the establishment of
electronic prescription registries. We ascertained medical his-
tory for cases and controls by extracting major diagnoses pre-
ceding index dates from the county hospital registries. We
also used these registries to identify all prediagnosis mam-
mography procedures for cases and controls since 2001, the
year mammography data began to be systematically recorded.
Definitions of analytic variables
We identified cases of incident breast cancer in the hospital
registries using ICD-8 and ICD-10 codes appropriate to the
date ranges of the databases. ICD codes were also used to
ascertain comorbid conditions for cases and controls (see full
ICD code listing in Table 1).
We ascertained CG prescriptions by extracting all records
from the prescription databases with ATC codes beginning
with C01A. CGs are available only by prescription in Denmark,
and are dispensed at pharmacies equipped with automated
electronic reporting systems described in the data collection
section. This strategy captured all CG prescriptions in the
counties over the study period that were for digoxin exclu-
sively. Digoxin prescriptions were only considered if they
occurred at least 1 year before the index date. Digoxin expo-
sure was considered in broad terms as ever exposed (≥ 1 dig-
oxin prescription at least 1 year before the index date) or never
exposed (no record of digoxin prescription at least 1 year
before the index date), and in finer terms according to the
length of time between a woman's first digoxin prescription
and her index date.
Confounders were selected a priori based upon established
breast cancer risk factors that were also likely to influence
receipt of digoxin. Age was initially controlled by matching
cases to controls on year of birth. We also calculated each
subject's exact age on her index date to adjust for residual
confounding by age. We additionally considered confounding
by coprescription of anticoagulants, non-steroidal anti-inflam-
matory drugs (NSAIDs), aspirin, and hormone replacement
therapy (HRT). Anticoagulants are frequently prescribed for
AF, and were associated with lower risk of urogenital cancer
[15]. NSAID use has been associated with increased risk of
CHF [16], and these drugs have shown protective associa-
tions with breast cancer in some studies [17]. Aspirin use,
which may be more prevalent among digoxin users, has beenAvailable online http://breast-cancer-research.com/content/10/6/R102
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associated with reduced breast cancer risk [18], though data
are conflicting [17]. We therefore evaluated confounding by
low- and high-dose aspirin use. We also evaluated HRT as a
confounder because of its contribution to cumulative hormonal
exposure and its association with breast cancer risk [19].
Prescriptions for hormone replacement therapy were identi-
fied by ATC codes (estrogens: codes starting with either
G03C or L02AA; progestin: codes beginning with G03D;
combination therapy: codes beginning with either G03F or
G03H). Exposure to any of these drugs before the index date
was classified as 'ever exposed to HRT' while exposure to
none of them was classified as 'never exposed to HRT'. Simi-
larly, we characterized ever/never exposure to anticoagulants,
NSAIDs and aspirin by searching for ATC codes beginning
with B01A, M01A, and B01AC06, respectively.
We evaluated confounding by the medical indications for dig-
oxin therapy by defining an alternative reference group of
women who were never exposed to digoxin and who had a his-
tory of cardiovascular disease (excluding CHF or AF). We
hypothesized these reference subjects should be more similar
to the digoxin-treated women with regard to cumulative hor-
monal exposures and lifestyle factors that may modify risk for
both heart disease and breast cancer. This reference group
also facilitated evaluation of detection bias by allowing com-
parison of digoxin-exposed women to women with other seri-
ous histories who would likely have similar medical usage
patterns. We further evaluated detection bias by comparing
mammography usage rates between cases and controls.
Dates of all mammography procedures among cases and con-
trols were identified in hospital registries using appropriate
Danish medical procedure codes. We analyzed mammogra-
phy usage among women with index dates from 1 January
2006 onward, the period of our study when screening mam-
mography would have been most common in Denmark. For
each subject who had undergone mammography before her
index date, we identified her most recent procedure and cal-
culated the time elapsed between that procedure and the
index date.
Statistical analysis
We characterized the names, doses, and prescribing frequen-
cies of the various digoxin products used over the study
period. We computed the frequency and proportion of cases
and controls by digoxin exposure status, prevalent medical
Table 1
Listing of ICD-8 and ICD-10 codes used to ascertain key diagnoses
Diagnosis ICD-8 ICD-10
Invasive breast carcinomaa 174.00 to 174.02; 174.08; 174.09; C50.0 to C50.6; C50.8; C50.9
Congestive heart failure 427.09; 427.10; 427.11; 427.19; 428.99; 
782.49
I50; I11.0; I13.0; I13.2
Atrial fibrillation/flutterb 427.93; 427.94 I48
Myocardial infarction 410 I21; I22; I23
Peripheral vascular disease 440; 441; 442; 443; 444; 445 I70; I71; I72; I73; I74; I77
Cerebrovascular disease 430 to 438 I60 to I69; G45; G46
Chronic pulmonary disease 490 to 493; 515 to 518 J40 to J47; J60 to J67; J68.4; J70.1; J70.3; 
J84.1; J92.0; J96.1; J98.2; J98.3
Mild liver disease 571; 573.01; 573.04 B18; K70.0 to K70.3; K70.9; K71; K73; K74; 
K76.0
Moderate to severe liver disease 070.00; 070.02; 070.04; 070.06; 070.08; 
573.00; 456.00 to 456.09
B15.0; B16.0; B16.2; B19.0; K70.4; K72; 
K76.6; I85
Diabetes type 1 249.00; 249.06; 249.07; 249.09 E10.0, E10.1; E10.9
Diabetes type 2 250.00; 250.06; 250.07; 250.09 E11.0; E11.1; E11.9
Moderate to severe renal disease 403; 404; 580 to 583; 584; 590.09; 593.19; 
753.10 to 753.19; 792
I12; I13; N00 to N05; N07; N11; N14; N17 to 
N19; Q61
Diabetes with end organ damage 
(types 1 and 2)
249.01 to 249.05; 249.08; 250.01 to 250.05; 
250.08
E10.2 to E10.8; E11.2 to E11.8
Solid tumor 140 to 194 C00 to C75
Lymphoma 200 to 203; 275.59 C81 to C85; C88; C90; C96
aThe ICD codes for invasive breast carcinoma do not capture in situ tumors (for example, intraductal carcinoma); bICD-8 contained separate 
codes for atrial fibrillation (427.93) and flutter (427.94). These two diagnoses were combined into a single code in ICD-10 (I48).
ICD, International Classification of Disease.Breast Cancer Research    Vol 10 No 6    Ahern et al.
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conditions, use of other prescription drugs (HRT, anticoagu-
lants, NSAIDs and aspirin), and age on index date.
We calculated the unadjusted odds ratios (ORs) and 95%
confidence intervals (CIs) associating digoxin exposure cate-
gories with incident breast cancer and used conditional logis-
tic regression to account for the matching factors and to
adjust for exact age and past use of HRT, anticoagulants,
NSAIDs, and aspirin. Due to the risk-set sampling design, the
odds ratio approximates the incidence rate ratio associating
digoxin exposure with incident breast cancer [20]. All analyses
were performed with SAS version 9 (SAS Institute, Cary, NC,
USA).
Results
Characteristics of cases and controls
We identified 5,565 cases and 55,650 matched population
controls. Among the cases, 324 (5.8%) had ever had a digoxin
prescription at least 1 year before her diagnosis date and
2,546 (4.6%) of controls had ever had a digoxin prescription
at least 1 year before her index date. The distributions of cases
and controls according to age, mammography usage, comor-
bidity and relevant prescription drug usage are shown in Table
2. By virtue of the matching, cases and controls were identical
with respect to age distribution. Cases were somewhat more
likely to have CHF, AF, chronic pulmonary disease, or diabe-
tes, and were less likely to have a history of myocardial infarc-
tion, than controls. Cases also had more exposure to HRT,
anticoagulants and NSAIDs than controls. As expected, mam-
mography usage was substantially higher for cases than for
controls in the year preceding the index date (81% vs 1.6%,
respectively). However, usage was similar for cases and con-
trols in time periods more distant from index dates.
Digoxin treatment and incident breast cancer
Table 3 shows all of the cardiac glycoside products recorded
in the county prescription registries during the study period.
We noted that digoxin was the sole CG used during this
period. Approximately 97% of all digoxin prescriptions were
for 62.5 μg tablets, indicating very little product heterogeneity
among the digoxin-exposed subjects.
We observed a higher rate of breast cancer among ever-users
of digoxin, relative to never users, in both unadjusted and
adjusted analyses (adjusted OR: 1.30; 95% CI: 1.14 to 1.48;
Table 4). This association persisted in categories of drug
exposure duration (1 to 3 years, 4 to 6 years and 7 to 18
years), with a suggested upward trend in the odds ratios with
increasing duration of digoxin therapy. When we compared
digoxin-exposed women with the alternative reference group
of unexposed women with cardiovascular medical histories,
we continued to observe an association between digoxin
exposure and incident breast cancer (adjusted OR: 1.42; 95%
CI: 1.14 to 1.77).
Discussion
Our results suggest there may be a causal association
between digoxin treatment and incident breast cancer in post-
menopausal women. These findings were robust to adjust-
ment for key confounders, confounding by indication, and
medical detection bias.
Interestingly, results from a case-control study by Stenkvist et
al. agree with our present findings. The investigators com-
pared the CG exposure history of the breast cancer cases
from their original report [2] to the exposure history of age-
matched controls from the general population [21]. The
authors concluded that CGs had no influence on breast can-
cer incidence, due to a non-significant chi-squared test for
independence (p = 0.25). The data from the published cross-
tabulation in fact yield an OR of 1.39, with a 95% CI of 0.79
to 2.45. While the interval is somewhat wide, the OR is near
to our result and consistent with a causal association between
CG use and incident breast cancer.
Other previous research is consistent with our results [7,22].
Haux and colleagues observed an elevated breast cancer rate
(standardized incidence ratio (SIR): 1.25; 95% CI: 0.95 to
1.62) among mostly postmenopausal digitoxin users, com-
pared with the rate in the general population [7]. The authors
also observed elevated SIR for several other cancer sites [7].
Friedman reported results from a Kaiser Permanente cohort
study of carcinogenic effects of prescription drugs, which
showed no statistically significant association between digi-
talis treatment and breast cancer incidence. However, the SIR
for this association was 1.2 – similar to the result of our study.
Ewertz et al. found a positive association between digoxin
usage and incident male breast cancer (OR for = 5 years of
digoxin use: 2.0; 95% CI: 0.9 to 4.4) [22]. Together these
results argue against ER antagonism by digitalis glycosides.
Our results are more consistent with an ER agonist property of
digoxin, though some in vitro ER binding studies do not sup-
port this notion [23,24].
Recent laboratory findings implicate the Na+/K+ ATPase in a
variety of signal transduction pathways, with end effects in cell
adhesion, survival, and proliferation [25]. Several in vitro stud-
ies point toward a downstream antiproliferative effect of CGs
but others leave open the possibility of cancer-promoting end-
points [26]. The interaction of cardiac glycosides with the
Na+/K+ ATPase and the consequential effects appear to be
highly dependent on the specific CG compound and the sub-
unit makeup of the receiving ATPase [6,26,27]. Therefore it
would not be surprising to observe inconsistent responses of
different human tissue types to the diverse cardiac glycosides.
Some of these ligand-, receptor-, and tissue-specific
responses may plausibly result in breast tumorigenesis in vivo,
consistent with our findings. With this study, we have isolated
the association between a single cardiac glycoside, digoxin,Available online http://breast-cancer-research.com/content/10/6/R102
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Table 2
Characteristics of the study sample
Variable Cases (n = 5,565) Controls (n = 55,650)
Age on index date (years):
55 to 64 2,116 (38) 21,160 (38)
65 to 74 1,800 (32) 18,000 (32)
75 to 84 1,356 (24) 13,560 (24)
≥ 85 293 (5.3) 2,930 (5.3)
Medical history, n (%):
Congestive heart failure 160 (2.9) 1,337 (2.4)
Atrial fibrillation/flutter 224 (4.0) 1,819 (3.3)
Prediagnosis mammographya
< 1 year: 417 (81) 84 (1.6)
1 to < 2 years: 3 (0.6) 84 (1.6)
2 to < 3 years: 9 (1.7) 84 (1.6)
≥ 3 years: 17 (3.3) 130 (2.5)
Myocardial infarction 123 (2.2) 1,492 (2.7)
Chronic pulmonary disease 334 (6.0) 3,125 (5.6)
Peripheral vascular disease 167 (3.0) 1,563 (2.8)
Cerebrovascular disease 275 (4.9) 2,842 (5.1)
Lymphoma 12 (0.2) 155 (0.3)
Other solid tumor 0 0
Liver disease 44 (0.8) 403 (0.7)
Diabetes (type I or II) 215 (3.9) 1,706 (3.1)
Diabetes with end-organ complication 85 (1.5) 591 (1.1)
Renal disease 35 (0.6) 446 (0.8)
Other drug exposures, n (%):
Hormone replacement therapy 2,062 (37) 17,582 (32)
Anticoagulants 231 (4.2) 2,109 (3.8)
NSAIDs 3,106 (56) 29,964 (54)
Aspirin, low-dose (< 150 mg) 205 (3.7) 2,004 (3.6)
Aspirin, high-dose (≥ 150 mg) 505 (9.1) 4,878 (8.8)
aScreening mammography data were only available from 2001 onwards. We restricted the mammography analysis to cases and controls with 
index dates after 1 January 2006, when screening mammography would have been most common in Denmark. Categories reflect time elapsed 
between most recent mammogram and index date; proportion denominators are the total number of cases (n = 516) or controls (n = 5,160) in the 
restricted data set.
NSAID, non-steroidal anti-inflammatory drug.Breast Cancer Research    Vol 10 No 6    Ahern et al.
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and breast cancer incidence in a virtually unselected popula-
tion of postmenopausal women.
Strengths and limitations
The main strengths of this study are its large size, use of high-
validity registry data to ascertain diagnoses, use of prospec-
tively-recorded exposure information, and lack of selection in
enumerating cases and controls.
Our study design minimized the threat of selection bias, which
can create the illusion of an exposure-disease association
when, in fact, none exists [28]. We had only one subject exclu-
sion criterion, and controls were selected completely at ran-
dom within strata of the matching factors. Since no subject
was required to give their consent to participate, no self-selec-
tion mechanism could have influenced our results.
Our results are subject to distortion by residual confounding
and misclassification of exposure and outcome. We took
measures to address confounding by age, past exposure to
other prescription drugs, and the medical indications for dig-
oxin prescription. We saw little change in the unadjusted asso-
ciation after accounting for these factors. Digoxin is ordinarily
prescribed at an age when most women no longer bear chil-
dren, so it is unlikely that digoxin exposure is strongly associ-
ated with the well-characterized reproductive factors that
affect breast cancer risk [29]. We therefore do not expect sub-
stantial residual confounding. It is unlikely that use of other pre-
scription drugs could bias our results, since antibiotics,
Table 3
All cardiac glycoside products prescribed to study subjectsa
Product name Dose Fill quantity No. of prescriptions, (% of total)
Digoxin 62.5 μg/tablet 100 tablets 83,094 (66)
62.5 μg/tablet 200 tablets 38,188 (31)
250 μg/tablet 100 tablets 4,047 (3.2)
50 μg/mL 30 mL 28 (0.02)
aResult of searching the prescription database for all Anatomical Therapeutic Chemical (ATC) codes beginning with 'C01A'.
Table 4
Associations between digoxin treatment and incident breast cancer
Exposure categories Cases (n = 5,565) Controls (n = 55,650) Unadjusted OR (95% CI) Adjusteda OR (95% CI)
Ever/never prescribed digoxin:
Ever user 324 2,546 1.29 (1.14 to 1.45) 1.30 (1.14 to 1.48)
Never user 5,241 53,104 1.0 (Ref) 1.0 (Ref)
Duration of digoxin therapy:b
7 to 18 years 93 694 1.35 (1.10 to 1.69) 1.39 (1.10 to 1.74)
4 to 6 years 103 811 1.29 (1.05 to 1.58) 1.30 (1.05 to 1.61)
1 to 3 years 128 1,041 1.25 (1.03 to 1.50) 1.25 (1.03 to 1.52)
Never user 5,241 53,104 1.0 (Ref) 1.0 (Ref)
Ever/never prescribed digoxin (alternate 
reference group):
(n = 732) (n = 7,086)
Ever user 324 2,546 1.42 (1.21 to 1.65) 1.42 (1.14 to 1.77)
Never userc 408 4,540 1.0 (Ref) 1.0 (Ref)
aAdjusted for age (continuous), county of residence (categorical), and past receipt of hormone replacement therapy, anticoagulants, high- and 
low-dose aspirin, and non-steroidal anti-inflammatory drugs (NSAIDs) (ever/never); byears elapsed between first digoxin prescription and index 
date (approximate tertiles of the distribution); cthe alternate reference group is additionally defined by a history of myocardial infarction, peripheral 
vascular disease, cerebrovascular disease, or any combination thereof. See text for rationale.
CI, confidence interval; OR, odds ratio.Available online http://breast-cancer-research.com/content/10/6/R102
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antihypertensives, statins, and antidepressants do not appear
to modify breast cancer risk [17]. Use of the alternative refer-
ence group resulted in a modest increase in the estimated
odds ratio; this result implies that confounding by indication
actually served to attenuate the original association. Further-
more, detection bias is not likely to account for the observed
association, since women with other cardiovascular diseases
would have similar medical usage to women treated with CG.
In the whole study population, we saw no material difference
in mammography usage rates between cases and controls in
time periods distant from index dates, which further argues
against detection bias.
We were not able to adjust directly for body mass index (BMI),
which is associated with both cardiovascular disease (CVD)
and breast cancer [30]. However our alternative reference
group likely controlled in part for BMI due to the association of
BMI with CVD [31]. Since the effect of adjustment via this ref-
erence group was to move the odds ratio estimate away from
the null, it is unlikely that unmeasured confounding by BMI
could account for our positive result.
Our characterization of digoxin exposure was informed only by
the number and strength of prescriptions filled by study partic-
ipants; the prescription registry data did not permit calculation
of actual daily doses taken by exposed subjects. Because pre-
scription records were generated automatically before breast
cancer diagnoses, we expect any exposure classification error
to be non-differential in nature. We are not aware of published
validation data on the classification of incident breast cancer
in the hospital discharge registries. However, breast cancer
diagnoses were recorded without express knowledge of expo-
sure, so outcome misclassification is also expected to be non-
differential. Since non-differential classification errors are
expected to attenuate results, exposure and outcome misclas-
sification cannot plausibly account for our positive association
[28].
Conclusion
We observed a modestly increased rate of breast cancer
among postmenopausal women with any history of digoxin
use, compared with women with no such use, after adjustment
for age, use of other prescription drugs, and cardiovascular
indications. The associations persisted in long-term exposure
categories. While a number of laboratory studies of cardiac
glycosides and female breast cancer have suggested protec-
tive effects, our results suggest that one specific cardiac gly-
coside, digoxin, moderately increases the incidence rate of
breast cancer. This finding agrees with results from past stud-
ies; [7,8,21] the importance of which were likely masked by
large standard errors of the association measures.
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